TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
IPO Year:
Exchange: NASDAQ
Website: therapeuticsmd.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $3.00 → $2.50 | Buy | HC Wainwright & Co. |
| 11/12/2021 | $4.00 → $3.00 | Buy | HC Wainwright & Co. |
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
4 - TherapeuticsMD, Inc. (0000025743) (Issuer)
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(2.3) million, or $(0.20) per basic and diluted common share, a decrease of $5.4 million, compared to net loss from continuing operations of $(7.7) million, or ($0.74) per basic and diluted common share, for 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $1.8 million during the year ended Dec
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(567) thousand, or $(0.05) per basic and diluted common share, compared to a net loss of $(1.4) million, or $(0.13) per basic and diluted common share, for the third quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $547 thousand for the third quarter of 2024, a
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(1.05) million, or $(0.09) per basic and diluted common share, compared to a net loss of $(2.4) million, or $(0.24) per basic and diluted common share, for the second quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $234 thousand for the second quarter of 2024, a
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(0.8) million, or $(0.07) per basic and diluted common share, compared to net loss from continuing operations of $(2.3) million, or $(0.24) per basic and diluted common share, for 2023. License and Service Revenues from Continuing Operations Gross license royalties totaled approximately $1.2 million under the Mayne License Agreement for the three months en
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023. "We continue to explore a variety of strategic alternatives with the goal of maximizing value for our shareholders," stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Full Year 2023 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(7.7) million, or $(0.74) per basic and diluted common share, compared to net income from continuing operations of $1.1 million, or
Focus remains on cost control to maximize the value of our royalty assets Company announces evaluation of strategic alternatives TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023. "As the Company continues its transition into a royalty-based business, we remain committed to cost control to maximize the value of our royalty assets," stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Third Quarter 2023 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $1.4 milli
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023. "The Company's transformation into a royalty-based business is ongoing. As we phase out our historical business operations, we remain focused on reducing costs and conserving cash," stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Second Quarter 2023 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $2.4 million for the quarter ended June 30, 2023, or $(0.24) per basic and diluted common share, compared to a net loss f
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $2.3 million for the quarter ended March 31, 2023, or $0.24 per basic and diluted common share, compared to a net loss from continuing operations of $17.9 million, or $2.08 per basic and diluted common share, for the comparable period in 2022. License and Service Revenues from Continuing Operations License and service revenues from continuing operations, which are r
TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022. "As a result of the transaction with Mayne Pharma Group Limited (ASX: MYX) ("Mayne Pharma") that closed at year-end, in which TherapeuticsMD granted Mayne Pharma an exclusive license to commercialize TherapeuticsMD's products in the United States, we repaid our debt, redeemed our outstanding preferred stock, eliminated our commercial and manufacturing infrastructure, and downsized our remaining operations," said Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. "We look forward
- Mayne Pharma gains exclusive U.S. commercialization rights for TXMD's products and acquires certain assets - - TXMD received approximately $153.1 million at closing; portion of proceeds used to repay all outstanding indebtedness under Sixth Street facility and redeem all outstanding preferred equity - - TXMD is eligible to receive up to $30.0 million in milestone payments and a minimum of $42.6 million in royalty payments - TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women's healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-lis